ArticleFrontiers in neurology2026

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.

Simone Huygens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.